Brain Tumor Treatments: Optune™
Braintumor Website

Last updated: 5/10/17

Click HERE to go to the "Official" Optune Website

High compliance with Optune linked to greatest survival benefit for glioblastoma 29% 5 year survival in high compliance group compared to 4.5% in control group.(Added 11/21/17)

No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators (Added 11/21/17)

Results from the trial for newly diagnoes GBM: 5 year survival rate more than double the standard of care! (added 9/24/17)

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma This may become the new standard of care for Glioblastoma multiforme! (added 12/15/15)

FDA Approves Optune for Newly Diagnosed Glioblastoma Patients. Risk of death reduced by 37%!

Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients Optune can now be used even if you have a non programmable shunt!

New data on how Tumor Treating Fields Works

The name of the treatment has been changed from Novocure TTF100-A to Optune on 11/14/2014

 Optune™ is a unique new form of treatment for brain tumors: it uses Tumor Treating Fields (TTF) to kill dividing cells. These fields are delivered by removable transducer arrays that are placed on the head.

This was approved by the United States FDA in 2011 for use in patients with recurrent glioblastoma multiforme and in 2015 for use in patients with newly diagnosed glioblastoma multifore

Tumor Treating Fields have been added to the NCCN guidelines as the standard of care for treatment of recurrent glioblastom multiform. See http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf (free registration is required).

Click HERE for a news video about the Novocure NovoTTF-100A!


Click on the links below for more information on Optune!
Disclosure: the Novocure company is a sponsor of our organization!
Novocure TTF100A - A New treatment for brain tumors!



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites